BR112018076169A2 - derivados azabenzimidazol como inibidores de pi3k beta - Google Patents
derivados azabenzimidazol como inibidores de pi3k betaInfo
- Publication number
- BR112018076169A2 BR112018076169A2 BR112018076169-9A BR112018076169A BR112018076169A2 BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2 BR 112018076169 A BR112018076169 A BR 112018076169A BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta inhibitors
- pi3k beta
- azabenzimidazole derivatives
- compounds
- azabenzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
a presente invenção refere-se a derivados azabenzimidazol de fórmula (i) em que as variáveis têm o significado definido nas reivindicações. os compostos de acordo com a presente invenção são úteis como inibidores de pi3kß. a invenção refere-se ainda a composições farmacêuticas compreendendo os referidos compostos como ingrediente ativo, bem como o uso dos referidos compostos como um medicamento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16174712 | 2016-06-16 | ||
EP16174712.6 | 2016-06-16 | ||
PCT/EP2017/064672 WO2017216293A1 (en) | 2016-06-16 | 2017-06-15 | Azabenzimidazole derivatives as pi3k beta inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018076169A2 true BR112018076169A2 (pt) | 2019-03-26 |
Family
ID=56132833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018076169-9A BR112018076169A2 (pt) | 2016-06-16 | 2017-06-15 | derivados azabenzimidazol como inibidores de pi3k beta |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190263804A1 (pt) |
EP (1) | EP3472147B1 (pt) |
JP (1) | JP7158286B2 (pt) |
KR (1) | KR102472198B1 (pt) |
CN (1) | CN109311843B (pt) |
AU (1) | AU2017286380B2 (pt) |
BR (1) | BR112018076169A2 (pt) |
CA (1) | CA3025746A1 (pt) |
EA (1) | EA037871B1 (pt) |
ES (1) | ES2818620T3 (pt) |
IL (1) | IL263653A (pt) |
MX (1) | MX2018015709A (pt) |
WO (1) | WO2017216293A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL298250A (en) | 2018-04-12 | 2023-01-01 | Bayer Ag | n-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-h1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridine-carboxamide derivatives Compatible as pest killers |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
FI3919486T3 (fi) | 2018-04-25 | 2023-08-23 | Bayer Ag | Uusia heteroaryylitriatsoli- ja heteroaryylitetratsoliyhdisteitä torjunta-aineina |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
JP2022541807A (ja) | 2019-07-23 | 2022-09-27 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としての新規なヘテロアリール-トリアゾール化合物 |
CN110551101B (zh) * | 2019-08-28 | 2020-11-24 | 沈阳药科大学 | 1、6-二取代-苯并五元杂环类衍生物及其用途 |
UY38911A (es) | 2019-10-09 | 2021-05-31 | Bayer Ag | Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos |
JP2023512205A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
WO2021154664A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
JP2023512204A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
EP4097100A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
CN115151546A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
US20230144824A1 (en) | 2020-01-27 | 2023-05-11 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230130516A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230041738A1 (en) | 2020-01-27 | 2023-02-09 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
EP4097104A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
WO2023155866A1 (zh) * | 2022-02-18 | 2023-08-24 | 四川海思科制药有限公司 | 一种吡唑并吡啶衍生物及其在医药上的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
JP2009528385A (ja) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害剤として用いるためのチアゾロン |
US20090215818A1 (en) | 2006-07-24 | 2009-08-27 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as pi3 kinase inhibitors |
EP2173354A4 (en) | 2007-08-09 | 2011-10-05 | Glaxosmithkline Llc | CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS |
RU2518098C2 (ru) * | 2007-10-05 | 2014-06-10 | Верастэм,Инк. | Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ и способ лечения пролиферативных заболеваний |
EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
EP2467141B1 (en) | 2009-08-17 | 2018-10-31 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
AU2010300719A1 (en) | 2009-09-29 | 2012-05-03 | Xcovery Holding Company Llc | PI3K (delta) selective inhibitors |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
HUE033209T2 (hu) | 2010-10-06 | 2017-11-28 | Glaxosmithkline Llc | PI3 kináz inhibitor hatású benzimidazol-származékok |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
WO2013095761A1 (en) | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
-
2017
- 2017-06-15 AU AU2017286380A patent/AU2017286380B2/en active Active
- 2017-06-15 ES ES17729500T patent/ES2818620T3/es active Active
- 2017-06-15 CA CA3025746A patent/CA3025746A1/en active Pending
- 2017-06-15 KR KR1020187037717A patent/KR102472198B1/ko active IP Right Grant
- 2017-06-15 EA EA201892734A patent/EA037871B1/ru not_active IP Right Cessation
- 2017-06-15 WO PCT/EP2017/064672 patent/WO2017216293A1/en unknown
- 2017-06-15 US US16/310,413 patent/US20190263804A1/en not_active Abandoned
- 2017-06-15 EP EP17729500.3A patent/EP3472147B1/en active Active
- 2017-06-15 CN CN201780037153.5A patent/CN109311843B/zh active Active
- 2017-06-15 BR BR112018076169-9A patent/BR112018076169A2/pt unknown
- 2017-06-15 JP JP2018565868A patent/JP7158286B2/ja active Active
- 2017-06-15 MX MX2018015709A patent/MX2018015709A/es active IP Right Grant
-
2018
- 2018-12-11 IL IL263653A patent/IL263653A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA3025746A1 (en) | 2017-12-21 |
KR102472198B1 (ko) | 2022-11-28 |
CN109311843B (zh) | 2021-10-08 |
US20190263804A1 (en) | 2019-08-29 |
CN109311843A (zh) | 2019-02-05 |
EP3472147A1 (en) | 2019-04-24 |
JP2019518059A (ja) | 2019-06-27 |
AU2017286380A1 (en) | 2018-12-06 |
AU2017286380B2 (en) | 2021-02-04 |
EA201892734A1 (ru) | 2019-05-31 |
WO2017216293A1 (en) | 2017-12-21 |
EP3472147B1 (en) | 2020-06-17 |
KR20190016976A (ko) | 2019-02-19 |
JP7158286B2 (ja) | 2022-10-21 |
EA037871B1 (ru) | 2021-05-28 |
IL263653A (en) | 2019-01-31 |
MX2018015709A (es) | 2019-03-21 |
ES2818620T3 (es) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018076169A2 (pt) | derivados azabenzimidazol como inibidores de pi3k beta | |
BR112018003595A2 (pt) | análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 | |
BR112018077015A2 (pt) | derivados de ácido borônico e usos terapêuticos dos mesmos | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
BR112016006651B8 (pt) | compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos | |
BR112012017442A2 (pt) | derivados de triazol bicíclicos substituídos como moduladores de gamma secretase | |
BR112018007068A2 (pt) | derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta | |
BR112015007183A2 (pt) | composições, uso de uma composição, método para o combate dos fungos e semente | |
BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
BR112013023984A2 (pt) | derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase | |
BR112015022566A2 (pt) | composto e composição farmacêutica | |
BR112019006414A2 (pt) | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112018005936A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112015024971A2 (pt) | derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk | |
BR112018011525A2 (pt) | inibidores da tirosina quinase de bruton e métodos de seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |